. . "For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, postoperation, and radiation. Also used for the treatment of postoperative nausea and vomiting."@en . . "Peter Bod, Kalman Harsanyi, Ferenc Trischler, Eva Fekecs, Attila Csehi, Bela Hegedus, Eva Mersich nee Donat, Gyorgyi Szabo nee Komlosi, Erika Horvath nee Sziki, \"Process for preparing ondansetron.\" U.S. Patent US5478949, issued September, 1990."@en . . . "approved"@en . . . . . . . "Ondansetron is a selective serotonin 5-HT₃ receptor antagonist. The antiemetic activity of the drug is brought about through the inhibition of 5-HT₃ receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT₃ receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone."@en . . . . . . . . . . . . . . . . . . . . . . . . . . . "* 0.38 L/h/kg [Normal Adult Volunteers (19-40 yrs)] * 0.32 L/h/kg [Normal Adult Volunteers (61-74 yrs)] * 0.26 L/h/kg [Normal Adult Volunteers (>=75 yrs)]"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Ondansetron is well absorbed after oral administration and undergoes limited first-pass metabolism."@en . . "Humans and other mammals"@en . . . . . . . . . . . . . . . . . . . . . . . "Take without regard to meals."@en . . . . . . . . " "@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Ondansetron"@en . . "5.7 hours"@en . . . . . . . . . . "Zofran odt"@en . . . . . . . . . . " "@en . "A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. [PubChem]"@en . . . . . . . . . . . . . . . . . . . . "# Ramsook C, Sahagun-Carreon I, Kozinetz CA, Moro-Sutherland D: A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med. 2002 Apr;39(4):397-403. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11919526 # Yilmaz HL, Yildizdas RD, Sertdemir Y: Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study. Aliment Pharmacol Ther. 2010 Jan;31(1):82-91. Epub . \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19758398 # Gregory RE, Ettinger DS: 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9506240 # Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15740177"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . "70%-76% (Plasma protein binding)"@en . . . . . . . . . . . . . . . . . . "Low blood pressure and fainting, sudden blindness, severe constipation"@en . . . . . . . . "99614-02-5"@en . . . . . . . . . . . . .